{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bone+Tumor&page=2", "query": { "condition": "Bone Tumor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bone+Tumor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T05:24:45.229Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04752163", "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Myelodysplastic Syndrome" ], "interventions": [ { "name": "DS-1594b", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-03-25", "completion_date": "2023-11-08", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-06-10T05:24:45.229Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752163" }, { "nct_id": "NCT01218477", "title": "Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "BMS-833923", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2011-01", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2016-06-17", "last_synced_at": "2026-06-10T05:24:45.229Z", "location_count": 3, "location_summary": "San Francisco, California • Baltimore, Maryland • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218477" }, { "nct_id": "NCT05316701", "title": "Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoid Leukemia", "Mixed Phenotype Acute Leukemia", "Undifferentiated Leukemia", "Myelodysplastic Syndrome", "Acute Leukemia", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Orca-T", "type": "BIOLOGICAL" }, { "name": "Standard-of-Care", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Orca Biosystems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 187, "start_date": "2022-06-21", "completion_date": "2026-07", "has_results": true, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-06-10T05:24:45.229Z", "location_count": 19, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05316701" }, { "nct_id": "NCT00008359", "title": "Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "caspofungin acetate", "type": "DRUG" }, { "name": "liposomal amphotericin B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2000-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-06-10T05:24:45.229Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008359" }, { "nct_id": "NCT00089245", "title": "Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Neuroblastoma", "Sarcoma" ], "interventions": [ { "name": "Iodine I 131 MOAB 8H9", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Y-mAbs Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 177, "start_date": "2004-02-05", "completion_date": "2022-02-02", "has_results": false, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-06-10T05:24:45.229Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089245" }, { "nct_id": "NCT01242072", "title": "Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignancy", "Cancer", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer", "Testicular Cancer", "Thymoma", "Ovarian Cancer", "Osteosarcoma" ], "interventions": [ { "name": "palifosfamide-tris", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2010-11", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-07-18", "last_synced_at": "2026-06-10T05:24:45.229Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Lafayette, Indiana • Muncie, Indiana + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Muncie", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01242072" }, { "nct_id": "NCT04308395", "title": "Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Basal Cell Nevus Syndrome" ], "interventions": [ { "name": "Patidegib Topical Gel, 2%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sol-Gel Technologies, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2020-06-03", "completion_date": "2021-07-14", "has_results": true, "last_update_posted_date": "2024-09-24", "last_synced_at": "2026-06-10T05:24:45.229Z", "location_count": 17, "location_summary": "Fremont, California • Newport Beach, California • New Haven, Connecticut + 14 more", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Ormond Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04308395" }, { "nct_id": "NCT04079296", "title": "A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "ASP7517", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2019-09-19", "completion_date": "2023-04-21", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-06-10T05:24:45.229Z", "location_count": 3, "location_summary": "Duarte, California • Pembroke Pines, Florida • New York, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04079296" }, { "nct_id": "NCT00045305", "title": "Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Photopheresis", "type": "DRUG" }, { "name": "Mycofenolate mofetil", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "allogeneic bone marrow", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell", "type": "PROCEDURE" }, { "name": "Total body irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 17, "start_date": "2006-10-24", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-06-10T05:24:45.229Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045305" }, { "nct_id": "NCT00586651", "title": "Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polycythemia Vera", "Essential Thrombocytosis" ], "interventions": [ { "name": "lestaurtinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cephalon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 39, "start_date": "2007-12", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2015-10-08", "last_synced_at": "2026-06-10T05:24:45.229Z", "location_count": 4, "location_summary": "Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00586651" } ] }